Waypoint Bio

Raised $20M in a Series A round, announced 27 May 2026.

Total raised: $20M

Latest round Series ACountry United StatesSector AI

Round

$20MSeries A, 27 May 2026

Series A to move lead program WAY-103 into an investigator-initiated trial in late 2026

Amount: $20M
Stage: Series A
Announced: 27 May 2026
Lead: Amplify Partners
Other investors: General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, Hummingbird Ventures
Use of funds: Series A to move lead program WAY-103 into an investigator-initiated trial in late 2026
Checked: Amount and date checked against the press source
Source: Waypoint Bio raises $20M Series A for AI-designed CAR-T endpoints.news

Company

AI-designed CAR-T cell therapies for solid tumors

Based in: New York, United States
Sector: AI
Website: waypointbio.com ↗

Questions

How much has Waypoint Bio raised?

Waypoint Bio raised $20M in a Series A round, announced on 27 May 2026.

Who invested in Waypoint Bio?

Amplify Partners led. Investors include Amplify Partners, General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital and Hummingbird Ventures.